AstraZeneca shares scientific updates from its extensive cardiovascular, renal and metabolic diseases (CVMD) portfolio at AHA 2017

AstraZeneca and MedImmune, its global biologics research and development arm, will be underlining its scientific focus on cardiovascular, renal and metabolic diseases (CVMD) with 28 presentations, including two late-breaking trials, at the American Heart Association (AHA) Scientific Sessions, November 11-15, 2017 in Anaheim, California.

Ludovic Helfgott, Vice President, Cardiovascular and Metabolic Diseases, said: “With the breadth of our scientific updates at AHA 2017, we are at the forefront of the clinical debate, exploring the often unseen but vital connections between cardiovascular, renal and metabolic diseases. This approach embodies our commitment to improving outcomes for patients while reducing long-term morbidity and mortality.”

Key among the data being presented are two late-breaking presentations selected by the AHA: the China-based DACAB study (Efficacy of Different Antiplatelet Therapy Strategy after Coronary Artery Bypass Grafting); and the EXSCEL (EXenatide Study of Cardiovascular Event Lowering) trial, plus data for potential new CVMD medicines.

  • The DACAB study compares the use of Brilinta (ticagrelor) plus aspirin versus aspirin alone, and Brilinta alone following elective coronary artery bypass graft surgery (CABG), to assess patency of the grafts. ( Session LBS.01 )
  • A new analysis of the EXSCEL clinical trial, the largest and most inclusive CV outcomes trial of any glucagon-like peptide-1 receptor agonist (GLP-1 RA), with more than 14,500 patients at 687 trial sites across 35 countries, aims to further demonstrate the effect of Bydureon (exenatide) once-weekly on CV morbidity and mortality in patients with type-2 diabetes. This new analysis adds to results presented at the recent annual meeting of the European Association for the Study of Diabetes (EASD), and published simultaneously in the New England Journal of Medicine . (Session LBS.04)
  • Presentations at AHA also include early stage data for potential new medicines, as monotherapy and in combinations, in areas including cardiac regeneration, chronic kidney disease, acute coronary syndromes, and chronic heart failure. These include Phase IIa data of MEDI6012, a recombinant human lecithin-cholesterol acyltransferase (LCAT) being evaluated for the treatment of coronary artery disease (Session LB.APS.06 – S2107) and CHF, as well as data from AZD5718 our 5-lipoxygenase activating protein (FLAP), a potential treatment for ACS (Session IN.APS.02 – S4093).  

ENDS

NOTES TO EDITORS

For the full listing of AstraZeneca/MedImmune Presentations at AHA 2017, please visit http://www.abstractsonline.com/pp8/#!/4412/  

About AstraZeneca in Cardiovascular, Renal & Metabolic Diseases (CVMD)

Cardiovascular, renal and metabolic diseases together form one of AstraZeneca’s main therapy areas and platforms for future growth. By following the science to understand more clearly the underlying links between the heart, kidney and pancreas, AstraZeneca is investing in a portfolio of medicines to protect organs and improve outcomes by slowing disease progression, reducing risks and tackling co-morbidities. Our ambition is to modify or halt the natural course of CVMDs and even regenerate organs and restore function, by continuing to deliver transformative science that improves treatment practices and CVMD health for millions of patients worldwide.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. 

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Relations
Esra Erkal-Paler UK/Global +44 203 749 5638
Karen Birmingham UK/Global +44 203 749 5634
Rob Skelding UK/Global +44 203 749 5821
Matt Kent UK/Global +44 203 749 5906
Gonzalo Viña UK/Global +44 203 749 5916
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677
Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Craig Marks Finance, Fixed Income, M&A +44 7881 615 764
Henry Wheeler Oncology +44 203 749 5797
Mitchell Chan Oncology +1 240 477 3771
Christer Gruvris Diabetes; Autoimmunity, Neuroscience & Infection +44 203 749 5711
Nick Stone Respiratory; Brilinta +44 203 749 5716
US toll free +1 866 381 7277

Om oss

AstraZeneca är ett globalt, innovationsdrivet bioläkemedelsföretag med fokus på forskning, utveckling och marknadsföring av receptbelagda läkemedel, primärt för behandling av sjukdomar inom tre terapiområden - andningsvägar, hjärta/kärl/metabolism och cancer men är också selektivt aktiv inom områdena neurovetenskap och autoimmunitet. AstraZeneca är verksamt i över 100 länder och våra innovativa läkemedel används av miljontals patienter världen över. Mer information finns på: www.astrazeneca.com och www.astrazeneca.se

Kontakt

Prenumerera